期刊文献+

ERCC1,p53和bcl-2表达与晚期非小细胞肺癌铂类化疗疗效的关系 被引量:7

Influences of ERCC1,p53 and bcl-2 expression on the therapeutic effects of advanced NSCLC patients with platinum-based chemotherapy
下载PDF
导出
摘要 目的研究核苷酸切除修复交叉互补基因1(ERCC1),抑癌基因p53(p53)和B细胞淋巴瘤因子2(bcl-2)基因的表达水平与晚期非小细胞肺癌(NSCLC)患者铂类化疗疗效的关系。方法收集晚期NSCLC患者的肿瘤组织并制备组织芯片,进行ERCC1,p53和bcl-2基因的免疫组织化学染色,检测其在NSCLC组织中的表达情况;同时采集患者外周血检测其血清中ERCC1,p53和bcl-2蛋白的表达情况。根据RECIST肿瘤化疗疗效的评价标准评价患者的疗效,分析影响NSCLC患者铂类化疗疗效的因素及3种基因的表达情况和疗效的关系。结果 ERCC1阴性表达和阳性表达时的化疗有效率分别为55.81%和25.58%(P<0.01);bcl-2阴性表达和阳性表达时的化疗有效率分别为45.28%和25%(P<0.05);p53阴性表达和阳性表达时的化疗有效率分别为53.85%和29.79%(P<0.05)。以ERCC1阴性,同时bcl-2阴性和p53阳性表达的患者人数为最多,与其他各组相比差异有统计学意义(P<0.05),而其他各组人数差异无统计学意义(P>0.05);以ERCC1阴性表达同时bcl-2阳性表达和p53阴性表达的患者采用铂类化疗的有效率为最高,与其他情况相比差异有统计学意义(P<0.05);而ERCC1,bcl-2和p53基因均为阳性表达时的化疗有效率最差,与其他情况相比差异有统计学意义(P<0.01)。结论 ERCC1,p53和bcl-2基因的表达水平可以作为预测NSCLC患者铂类化疗疗效和预后的指标。 Objective The aim of this study was to assess the influences of ERCC1,p53 and bcl-2 expression levels on the therapeutic effects of terminal NSCLC platinum-based chemotherapy. Methods ERCC1,p53 and bcl-2 protein expression levels were assessed in patients' peripheral blood serum; the influencing factors of the curative effects of platinum-based chemotherapy on NSCLC patients were assessed, and the relationship between the expression levels of the three genes and their curative effects were analyzed. Results The chemotherapy efficiency of ERCC1 negative expression and ERCC1 positive expression were 55.81% and 25.58%, respectively (P〈0.01),those of bcl-2 were 45.28%and 25.00%, respectively (P〈0.05), and those of p53 were 53.85%and 29.79%, respectively (P 〈 0.05). There were no obvious correlations between ERCC1,p53 and bcl-2 expression levels; the effectiveness of chemotherapy was highest in patients with ERCC1 negative expression ,bcl-2 positive expression and p53 negative expression,compared with other situations; a significant difference was found (P 〈 0.05). The effectiveness of chemotherapy was lowest when the expressions of ERCC1,p53 and bcl-2 were positive (P 〈 0.01). Conclusion In serum,the expression levels of ERCC1,p53 and bcl-2 can be considered indicators of the therapeutic effects of platinum-based chemotherapy in NSCLC patients.
作者 郑瑞锋 罗俊波 王彦威 文海英 申培红 Zheng Ruifeng Luo Junbo Wang Yanwei et al(Department of Radiology,Armed Police Crops Hospital of Henan Province, Zhengzhou 450000, Chin)
出处 《中华保健医学杂志》 2017年第2期148-152,共5页 Chinese Journal of Health Care and Medicine
关键词 NSCLC ERCC1 P53 bcl-2 铂类化疗 基因 NSCLC ERCC1 p53 bcl-2 Platinum chemotherapy Gene
  • 相关文献

参考文献8

二级参考文献68

共引文献69

同被引文献73

二级引证文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部